{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,15]],"date-time":"2026-09-15T19:18:23Z","timestamp":1789499903906,"version":"build-2803163510"},"reference-count":25,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"42","license":[{"start":{"date-parts":[[2025,10,17]],"date-time":"2025-10-17T00:00:00Z","timestamp":1760659200000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2025,10,17]]},"abstract":"<jats:p>A preservative-free intranasal formulation of varenicline (Tyrvaya) has been developed and approved in the United States for the treatment of the signs and symptoms of dry eye disease (DED). Given its growing use in the clinical treatment of DED, understanding its safety in real-world settings is essential. This study aims to further assess the safety concerns after the launch of Tyrvaya. This study analyzed all adverse events (AEs) reports from the FDA Adverse Event Reporting System database, in which Tyrvaya was identified as the primary suspected drug, starting from the fourth quarter of 2021, to evaluate its safety in clinical practice. To ensure the accuracy and reliability of the study, we employed 4 types of disproportionality analyses: the reporting odds ratio, proportional reporting ratio, multi-item gamma Poisson shrinker (MGPS), and Bayesian confidence propagation neural network. Additionally, the Weibull distribution was utilized to model the risk of AEs over time. A total of 2178 patients and 5189 reports associated with Tyrvaya administration were collected. Positive signal detection of Tyrvaya at the system organ class level included respiratory, thoracic, and mediastinal disorders, product issues, and eye disorders. At the preferred term level, the AEs listed on the drug label were confirmed, including sneezing, cough, throat irritation, and instillation-site (nasal) irritation. Furthermore, several adverse reactions not listed in the medication leaflet but deemed clinically significant were identified, including blurred vision, burning sensation, upper-airway cough syndrome, nasal ulcers, dysphonia, abnormal dreams, photophobia, and eye swelling. Additionally, we identified potential adverse reactions, including headache, insomnia, and vertigo. This study identified known AEs associated with Tyrvaya and uncovered new AE signals that had not been previously reported. These findings offer clinicians additional safety insights for the use of Tyrvaya in treating DED.<\/jats:p>","DOI":"10.1097\/md.0000000000045032","type":"journal-article","created":{"date-parts":[[2025,11,3]],"date-time":"2025-11-03T23:01:10Z","timestamp":1762210870000},"page":"e45032","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":1,"title":["Post-marketing safety assessment of Tyrvaya: A real-world pharmacovigilance analysis based on the FDA Adverse Event Reporting System"],"prefix":"10.1097","volume":"104","author":[{"ORCID":"https:\/\/orcid.org\/0009-0001-2345-9792","authenticated-orcid":false,"given":"Chang-Zhu","family":"He","sequence":"first","affiliation":[{"name":"Chengdu University of Traditional Chinese Medicine, Chengdu, Sichuan, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qin","family":"Qiu","sequence":"additional","affiliation":[{"name":"Chengdu University of Traditional Chinese Medicine, Chengdu, Sichuan, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Song-Jie","family":"Lu","sequence":"additional","affiliation":[{"name":"Chengdu University of Traditional Chinese Medicine, Chengdu, Sichuan, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fu-Li","family":"Xue","sequence":"additional","affiliation":[{"name":"Chengdu University of Traditional Chinese Medicine, Chengdu, Sichuan, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wei-Yu","family":"Wang","sequence":"additional","affiliation":[{"name":"Chengdu University of Traditional Chinese Medicine, Chengdu, Sichuan, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9319-737X","authenticated-orcid":false,"given":"Yu","family":"He","sequence":"additional","affiliation":[{"name":"Department of Ophthalmology, Chengdu First People\u2019s Hospital\/Chengdu Integrated TCM and Western Medicine Hospital, Chengdu, Sichuan, China."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-20260915","doi-asserted-by":"crossref","first-page":"276","DOI":"10.1016\/j.jtos.2017.05.008","article-title":"TFOS DEWS II definition and classification report.","volume":"15","author":"Craig","year":"2017","journal-title":"Ocul Surf"},{"key":"R2-20260915","first-page":"e54028","article-title":"Dry eye disease: an overview of its risk factors, diagnosis, and prevalence by age, sex, and race.","volume":"16","author":"Deo","year":"2024","journal-title":"Cureus"},{"key":"R3-20260915","doi-asserted-by":"crossref","first-page":"1254","DOI":"10.1111\/opo.12888","article-title":"The global prevalence of dry eye disease: a Bayesian view.","volume":"41","author":"Papas","year":"2021","journal-title":"Ophthalmic Physiol Opt"},{"key":"R4-20260915","first-page":"19","article-title":"Managing dry eye disease with novel medications: mechanism, study validity, safety, efficacy, and practical application.","volume":"12","author":"Wong","year":"2024","journal-title":"Pharmacy (Basel)"},{"key":"R5-20260915","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1186\/s12886-023-03069-y","article-title":"The efficacy and safety of varenicline nasal spray for the management of dry eye signs: a systematic review and meta-analysis.","volume":"23","author":"Bashrahil","year":"2023","journal-title":"BMC Ophthalmol"},{"key":"R6-20260915","doi-asserted-by":"crossref","first-page":"801","DOI":"10.1124\/mol.106.025130","article-title":"Varenicline is a partial agonist at alpha4beta2 and a full agonist at alpha7 neuronal nicotinic receptors.","volume":"70","author":"Mihalak","year":"2006","journal-title":"Mol Pharmacol"},{"key":"R7-20260915","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1124\/jpet.112.194852","article-title":"Varenicline is a potent partial agonist at \u03b16\u03b22* nicotinic acetylcholine receptors in rat and monkey striatum.","volume":"342","author":"Bordia","year":"2012","journal-title":"J Pharmacol Exp Ther"},{"key":"R8-20260915","first-page":"101032","article-title":"Varenicline solution nasal spray for dry eye disease in Chinese patients: a randomized phase 3 trial.","volume":"45","author":"Tian","year":"2024","journal-title":"Lancet Reg Health West Pac"},{"key":"R9-20260915","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1016\/j.ophtha.2021.11.004","article-title":"Efficacy and safety of OC-01 (varenicline solution) nasal spray on signs and symptoms of dry eye disease: the ONSET-2 phase 3 randomized trial.","volume":"129","author":"Wirta","year":"2022","journal-title":"Ophthalmology"},{"key":"R10-20260915","doi-asserted-by":"crossref","first-page":"1463","DOI":"10.1016\/j.clinthera.2022.09.013","article-title":"Bilateral effect of OC-01 (varenicline solution) nasal spray for treatment of signs and symptoms in individuals with mild, moderate, and severe dry eye disease.","volume":"44","author":"Katz","year":"2022","journal-title":"Clin Ther"},{"key":"R11-20260915","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1016\/j.jtos.2022.05.001","article-title":"Nicotinic acetylcholine receptor stimulation: a new approach for stimulating tear secretion in dry eye disease.","volume":"25","author":"Pflugfelder","year":"2022","journal-title":"Ocul Surf"},{"key":"R12-20260915","doi-asserted-by":"crossref","first-page":"102097","DOI":"10.1016\/j.clae.2023.102097","article-title":"Efficacy of bilateral OC-01 (varenicline solution) nasal spray in alleviating signs and symptoms of dry eye disease: a systematic review.","volume":"47","author":"Ballesteros-S\u00e1nchez","year":"2024","journal-title":"Cont Lens Anterior Eye"},{"key":"R13-20260915","doi-asserted-by":"crossref","first-page":"1393940","DOI":"10.3389\/fphar.2024.1393940","article-title":"Adverse event reporting of the IGF-1R monoclonal antibody teprotumumab: a real-world study based on the US food and drug administration adverse event reporting system.","volume":"15","author":"Zhao","year":"2024","journal-title":"Front Pharmacol"},{"key":"R14-20260915","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1002\/pds.1001","article-title":"The reporting odds ratio and its advantages over the proportional reporting ratio.","volume":"13","author":"Rothman","year":"2004","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"R15-20260915","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1002\/pds.677","article-title":"Use of proportional reporting ratios (PRRs) for signal generation from spontaneous adverse drug reaction reports.","volume":"10","author":"Evans","year":"2001","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"R16-20260915","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1007\/s002280050466","article-title":"A Bayesian neural network method for adverse drug reaction signal generation.","volume":"54","author":"Bate","year":"1998","journal-title":"Eur J Clin Pharmacol"},{"key":"R17-20260915","doi-asserted-by":"crossref","first-page":"1099","DOI":"10.1592\/phco.24.13.1099.38090","article-title":"Pharmacovigilance in the 21st century: new systematic tools for an old problem.","volume":"24","author":"Szarfman","year":"2004","journal-title":"Pharmacotherapy"},{"key":"R18-20260915","doi-asserted-by":"crossref","first-page":"1408135","DOI":"10.3389\/fphar.2024.1408135","article-title":"A real-world disproportionality analysis of Tivozanib data mining of the public version of FDA adverse event reporting system.","volume":"15","author":"Wang","year":"2024","journal-title":"Front Pharmacol"},{"key":"R19-20260915","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1016\/j.ajo.2023.09.024","article-title":"United States regulatory approval of topical treatments for dry eye.","volume":"258","author":"Cui","year":"2024","journal-title":"Am J Ophthalmol"},{"key":"R20-20260915","doi-asserted-by":"crossref","first-page":"1448","DOI":"10.1177\/08971900221108725","article-title":"Intranasal varenicline: review of a novel formulation for the treatment of dry eye disease.","volume":"36","author":"Zitko","year":"2023","journal-title":"J Pharm Pract"},{"key":"R21-20260915","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1016\/j.jtos.2021.12.007","article-title":"A phase II randomized trial to evaluate the long-term (12-week) efficacy and safety of OC-01 (varenicline solution) nasal spray for dry eye disease: the MYSTIC study.","volume":"24","author":"Quiroz-Mercado","year":"2022","journal-title":"Ocul Surf"},{"key":"R22-20260915","doi-asserted-by":"crossref","first-page":"1207","DOI":"10.1097\/ICO.0000000000002941","article-title":"ONSET-1 phase 2b randomized trial to evaluate the safety and efficacy of OC-01 (varenicline solution) nasal spray on signs and symptoms of dry eye disease.","volume":"41","author":"Wirta","year":"2022","journal-title":"Cornea"},{"key":"R23-20260915","doi-asserted-by":"crossref","first-page":"1178","DOI":"10.1016\/j.clinthera.2022.07.006","article-title":"Efficacy and safety of single-dose OC-02 (simpinicline solution) nasal spray on signs and symptoms of dry eye disease: the PEARL phase II randomized trial.","volume":"44","author":"Torkildsen","year":"2022","journal-title":"Clin Ther"},{"key":"R24-20260915","doi-asserted-by":"crossref","first-page":"e220215","DOI":"10.57264\/cer-2022-0215","article-title":"Safety, adherence and discontinuation in varenicline solution nasal spray clinical trials for dry eye disease.","volume":"12","author":"Hauswirth","year":"2023","journal-title":"J Comp Eff Res"},{"key":"R25-20260915","doi-asserted-by":"crossref","first-page":"1481","DOI":"10.1007\/s40265-022-01782-4","article-title":"Varenicline solution nasal spray: a review in dry eye disease.","volume":"82","author":"Frampton","year":"2022","journal-title":"Drugs"}],"container-title":["Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/10.1097\/MD.0000000000045032","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,15]],"date-time":"2026-09-15T19:00:57Z","timestamp":1789498857000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/10.1097\/MD.0000000000045032"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10,17]]},"references-count":25,"journal-issue":{"issue":"42","published-print":{"date-parts":[[2025]]}},"URL":"https:\/\/doi.org\/10.1097\/md.0000000000045032","relation":{},"ISSN":["0025-7974","1536-5964"],"issn-type":[{"value":"0025-7974","type":"print"},{"value":"1536-5964","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,10,17]]},"assertion":[{"value":"2024-10-31","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-09-15","name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}}]}}